Document:

DEVELOPMENT AGREEMENT DATED JUNE 6, 1997

 EXHIBIT 10.24 
  
 July 14, 1997 
  
 C3, Inc. 
 One Dominion Drive, Suite 106 
 Morrisville. NC 25670 
  

	 	Re:	 	Development Agreement Dated as of June 6, 1997 (the “Development Agreement”), and Amended and Restated Supply Agreement Dated as of June 6, 1997 (the “Supply
Agreement”), between C3, Inc. and Cree Research, Inc. 

  
 Gentlemen: 
  
 This letter confirms the following
representations made by, and understandings reached between, C3, Inc. (“C3”) and Cree Research, Inc. (“Cree”) in connection with the execution of the Development Agreement and Supply Agreement referenced above: 
  
 1. Notwithstanding any other provision of the Supply Agreement, the price to
C3 for [***] diameter production silicon carbide (SIC) boules purchased under the Supply Agreement on an “as is” basis prior to July 1, 1998 shall not exceed [***] per boule, including the cost of removal of the seed. 
  
 2. For purposes of Section 5.8 of the Supply Agreement, “post Faceting
process” means the process of oxidizing SiC gems after faceting in order to reduce the effects of cutting damage, using the methods developed before June 6, 1997, and “improvements” means any modification of such process useful for
reducing the effects of cutting damage in SiC gems. 
  
 3. C3
acknowledges that it has not given Cree any notice under Section 1.2 of the Supply Agreement prior to the date of this letter. 
  
 4. C3 acknowledges and agrees that, except as provided otherwise in the letter agreements between C3 and Cree dated January 31, 1996, and February 12,
1996, the Assignment Agreement dated June 28, 1995 (as amended September 15, 1995), and Section 5.8 of the Supply Agreement, nothing in any agreement, purchase order or other arrangement between Cree and C3 gives C3 ownership rights in or any
license with respect to any invention made or conceived by Cree personnel prior to the date hereof, whether alone by Cree personnel or jointly with Cree and C3 personnel. 
  
 [***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission.
Omitted portions have been filed separately with the Commission. 

 July 14, 1997 
 Page 2 
  
 5. Cree shall have [***] as the lead scientist (100% of his effort) for the work to be performed for C3 pursuant to the Development Agreement through June
30, 1998, provided that [***] remains an employee of Cree and C3 does not reduce its funding obligations under Section 2.3 of the Development Agreement. 
  
 6. C3 acknowledges that the license granted pursuant to the letter agreement between C3 and Cree dated January 31, 1996 does not include a license to any
invention other than that claimed in U.S. Patent Application Serial No. 08/596,526, entitled “Growth of Colorless Silicon Carbide Crystals,” and, in particular, does not include a license to practice the methods claimed in U.S. Patent No.
Re34,861, entitled “Sublimation of Silicon Carbide to Produce Large, Device Quality Single Crystals of Silicon Carbide.” 
  
 7. The contents of this letter shall be considered “Confidential Information” of each party subject to the provisions of Section 5 of the Supply
Agreement. 
  
 If you agree that the foregoing accurately states
our understanding regarding the subject matter addressed above, please indicate your agreement on behalf of C3 by signing below. 
  

	 Very truly yours,

	
	 CREE RESEARCH, INC.

		
	By:	 	/s/    CHARLES M. SWOBODA
	 	

	 	 	 Charles M. Swoboda,
 Vice President and Chief Operating Officer

  

	Agreed:
	
	 C3, INc.

		
	By:	 	/s/    JEFF N. HUNTER
	 	

	 	 	 Jeff N. Hunter,
 President

  
 [***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.DEVELOPMENT AGREEMENT DATED AS OF JUNE 6, 1997

 EXHIBIT 10.25 
  
 July 14, 1997 
  
 C3, Inc. 
 One Dominion Drive, Suite 106 
 Morrisville. NC 25670 
  

	 	Re:	 	Development Agreement Dated as of June 6, 1997 (the “Development Agreement”), and Amended and Restated Supply Agreement Dated as of June 6, 1997 (the “Supply
Agreement”), between C3, Inc. and Cree Research, Inc. 

  
 Gentlemen: 
  
 This letter confirms the following
representations made by, and understandings reached between, C3, Inc. (“C3”) and Cree Research, Inc. (“Cree”) in connection with the execution of the Development Agreement and Supply Agreement referenced above: 
  
 1. Notwithstanding any other provision of the Supply Agreement, the price to
C3 for [***] diameter production silicon carbide (SIC) boules purchased under the Supply Agreement on an “as is” basis prior to July 1, 1998 shall not exceed [***] per boule, including the cost of removal of the seed. 
  
 2. C3 acknowledges that it has not given Cree any notice under Section 1.2 of
the Supply Agreement prior to the date of this letter. 
  
 3. C3
acknowledges and agrees that, except as provided otherwise in the letter agreements between C3 and Cree dated January 31, 1996, and February 12, 1996, the Assignment Agreement dated June 28, 1995 (as amended September 15, 1995), and Section 5.8 of
the Supply Agreement, nothing in any agreement, purchase order or other arrangement between Cree and C3 gives C3 ownership rights in or any license with respect to any invention made or conceived by Cree personnel prior to the date hereof, whether
alone by Cree personnel or jointly with Cree and C3 personnel. 
  
 4. Cree shall have [***] as the lead scientist (100% of his effort) for the work to be performed for C3 pursuant to the Development Agreement through June 30, 1998, provided that [***] remains an employee of Cree and C3 does not reduce its
funding obligations under Section 2.3 of the Development Agreement. 
  
 5. C3 acknowledges that the license granted pursuant to the letter agreement between C3 and Cree dated January 31, 1996 does not include a license to any invention other than that claimed in U.S. Patent Application Serial No. 08/596,526,
entitled “Growth of Colorless Silicon Carbide Crystals,” and, in particular, does not include a license to practice the methods claimed in U.S. Patent No. Re34,861, entitled “Sublimation of Silicon Carbide to Produce Large, Device
Quality Single Crystals of Silicon Carbide.” 
  
 [***] Confidential treatment
requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. 

 July 14, 1997 
 Page 2 
  
 6. The contents of this letter shall be considered “Confidential Information” of each party subject to the provisions of Section 5 of the Supply
Agreement. 
  
 If you agree that the foregoing accurately states
our understanding regarding the subject matter addressed above, please indicate your agreement on behalf of C3 by signing below. 
  

	 Very truly yours,

	
	 CREE RESEARCH, INC.

		
	 By:
	 	 /s/    CHARLES M. SWOBODA

	 	 	 Charles M. Swoboda,
 Vice President and Chief Operating Officer

  

	Agreed:
	
	C3, INC.
		
	 By:
	 	 /s/    JEFF N. HUNTER

	 	 	 Jeff N. Hunter,
 PresidentLETTER AGREEMENT DATED 8-5-02 BETWEEN CHARLES & COLVARD AND CREE

 EXHIBIT 10.26 
  
 August 5, 2002 
  

	 Robert S. Thomas
	 	 Charles M. Swoboda

	 President & CEO
	 	 President & CEO

	 Charles & Colvard, Ltd.
	 	 Cree, Inc.

	 3800 Gateway Blvd. Suite 310
	 	 4600 Silicon Drive

	 Morrisville, NC 27560
	 	 Durham, NC 27703

  
 This letter, when signed on behalf of
Charles & Colvard, Ltd. (formerly C3 Inc.) and Cree, Inc., will serve as an agreement between Charles & Colvard and Cree amending the parties’ March 8, 2002 letter agreement to provide the following terms, effective on and after July 1,
2002. As defined in the March 8, 2002 letter agreement, the development agreement will expire upon Charles & Colvard’s purchasing the quantity of SiC production crystals specified in that agreement. 
  

	 	1.	 	Cree will supply SiC production crystals to Charles & Colvard, and Charles & Colvard will purchase SiC production crystals from Cree, according to the terms stated in this
agreement. 

  

	 	2.	 	Charles & Colvard will purchase “usable material” (determined in the manner described in Paragraph 3) at a price of $[***] and according to the following quantities
and schedule for the period of six months beginning July 1, 2002. Prices for purchases after calendar 2002 will be mutually agreed in writing from time to time. 

  

	 Delivery Period

	 	 Quantity (kg)

	 7/1/02 – 9/29/02
	 	[***]
	 9/30/02 – 12/29/02
	 	[***]

  
 Provided that Cree
uses its best commercially reasonable efforts to deliver the quantities of usable material required by this agreement, Cree will not be held in breach for delays in delivery. 
  

	 	3.	 	The quantity of “usable material” of crystals delivered to Charles & Colvard pursuant to this agreement will be determined according to the following:

  

	 	A.	 	Material will be graded according to specifications in Attachment A. 

  

	 	B.	 	Grams of usable material will be calculated on a crystal by crystal basis according to the following equation: (usable mm) as a percent of total length of the crystal in mm
multiplied by the actual weight of the crystal in grams. “Usable mm” means millimeters of usable material as defined in Attachment A. 

  

	 	C.	 	Crystals shipped to Charles & Colvard must contain at least [***] grams of usable material for the 2” crystals or [***] grams for 3” crystals. This usable area must be
contiguous. Crystal diameter to be shipped will be 2” or 3” as determined by Cree. 

  

	 	4.	 	Charles & Colvard agrees to purchase a minimum of [***] of “usable material” (calculated in the manner described in Paragraph 3) each quarter during calendar 2003. For
each quarter in calendar 2003 and thereafter, Charles & Colvard will provide Cree its minimum volume requirements in the form of firm purchase orders at least 30 days in advance of the quarter. For each quarter during the period beginning
January 2003 and ending September 2007, in the event that (i) the minimum volume requirements of Charles & Colvard fall below [***] per quarter and (ii) Cree 

  
 [***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission.
Omitted portions have been filed separately with the Commission. 

	 	   	 	has not utilized on a daily basis as described below, for production for Charles & Colvard or for other Cree production, at least [***] crystal growers designated by Cree for
the production of materials for Charles & Colvard, then Charles & Colvard agrees to pay Cree an unused capacity charge for the under utilized portion such crystal growers, up to a maximum charge of $111,222 per quarter. The charge per grower
will be calculated as the product of $[***] per day times the number of days during the quarter on which no production runs were started in the grower for production for Charles & Colvard or for other Cree production. Cree will invoice the
unused capacity charge on a quarterly basis on or after the last business day of each quarter; payment is due 30 days after the invoice date. As used in this agreement, “quarter” refers to fiscal quarters of Cree ending during the
indicated period. 

  

	 	5.	 	Except as provided above, the supply and purchase of SiC material will be governed by the terms and conditions of the parties’ Supply Agreement, as amended.

  

	 	6.	 	The contents of this letter shall be considered “Confidential Information” of each party subject to the provisions of Section 5 of the Supply Agreement, as amended.

  

	 CHARLES & COLVARD, LTD.
	 	 	 	 CREE, INC.

					
	By:	 	/s/    ROBERT S. THOMAS        	 	 	 	By:	 	/s/    CHARLES M. SWOBODA        
	 	
	 	 	 	 	

	 	 	 Robert S. Thomas
 President & CEO
 Charles & Colvard Ltd.
	 	 	 	 	 	 Charles M. Swoboda
 President & CEO
 Cree, Inc.

  
 [***] Confidential treatment requested
pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission. 

 ATTACHMENT A 
  
 Specification of usable material as referenced in paragraph 2 above. 
  
 COLOR: Usable material is calculated as “light gray” or “very light gray”. Specifically tone/color number
20 and 10 1 as used in the Charles & Colvard boule-grading screen will be considered acceptable tone and color
material (note: grade 10 is preferred. Grade 20 material will be valued at $[***] per-gram). 
  
 DEFECTS: 
  
 Material volume of
acceptable color will be reduced by the percentage of the defects listed in the table below. Charles & Colvard shall set the acceptable standards for the quality of both the color and defects of all material purchased pursuant to this letter
agreement. For pricing purposes the grading of the material by both Cree and Charles & Colvard will adhere to those standards from which a baseline has been established during the grading of 206 crystals during the first quarter of 2002. Should
Charles & Colvard deem current standards or new defects unacceptable, then it can request changes to the standards or to the list of price reducing defects. At such time Cree has the option to make changes to its materials pricing and/or volume
commitments. 
  

	ID

	  	 D-Type

	  	 
	 1
	  	[***]	  	Reduce
	 2
	  	[***]	  	Reduce
	 3
	  	[***]	  	Reduce
	 4
	  	[***]	  	No reduction
	 5
	  	[***]	  	Reduce
	 6
	  	[***]	  	Reduce
	 7
	  	[***]	  	No reduction
	 8
	  	[***]	  	Reduce
	 9
	  	[***]	  	Reduce

  

	1	 	CH0257R 17.4mm tone/color 20 (lightest 20), new gray boules that are lighter than this will grade as 10, CE0269R 9.5mm tone/color 30 (lightest 30), new gray boules that are
lighter than this will grade as 20 

  

	2	 	Grading standards representing [***]= CF0228R (30%med.), CF0229R (15%med.), CF0230R (50%med.), CE0270R (100%med.) & CE0264R (100%med.). 

  

	3	 	[***] are represented by boule numbers CF0226R, CH0257R, CH0258R, CH0260R, CH0262R, CJ0192R, CS0165R, CS0166R, CS0168R, CS0169R. 

  

	4	 	Crystals CC0213R, CH0165R and CH0215R represent [***] grading. 

  
 [***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been
filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]